From smart pill bottles that help people remember to take their meds to calls for better menopausal symptom relief for women with breast cancer to intriguing hints at what drives dormant tumor cells ...
Giredestrant significantly improves invasive disease-free survival in ER+/HER2– early breast cancer, reducing recurrence or death risk by 30% compared to standard endocrine therapy. Tukysa, combined ...
Atezolizumab, combined with chemotherapy, did not improve survival in high-risk triple-negative breast cancer and had higher severe adverse events. A Swedish study found 30% of breast cancers were ...
Avan Armaghani, MD, reviews three key topics in the management of hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer to be explored at this year’s ...
Dr Harold J. Burstein of the Dana-Farber Cancer Institute, Boston, highlights key ER+ breast cancer abstracts from the 2025 San Antonio Breast Cancer Symposium. Beginning with the metastatic setting, ...
SABCS 2025 will address key topics such as alcohol's impact on breast cancer, lobular breast cancer, and breast cancer in young women. The symposium will present new research, including significant ...
Scientists at the University of Pennsylvania have shown for the first time that it’s possible to detect dormant cancer cells in breast cancer survivors and eliminate them with repurposed drugs, ...
Researchers found that triple-negative breast cancer cells are “addicted” to lipids, a feature tied to obesity. By studying mice, they discovered that high lipid levels alone accelerate tumor growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results